Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 31 Carcinoma, Hepatocellular 18 Neoplasms 13 Neoplasm Metastasis 13 Melanoma 13 Esophageal Neoplasms 12 Nasopharyngeal Carcinoma 10 Head and Neck Neoplasms 9 Esophageal Squamous Cell Carcinoma 9 Colorectal Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 8 Breast Neoplasms 8 Triple Negative Breast Neoplasms 7 Stomach Neoplasms 7 Recurrence 7 Pancreatic Neoplasms 7 Rectal Neoplasms 6 Carcinoma, Renal Cell 6 Biliary Tract Neoplasms 6 Lung Neoplasms 5 Small Cell Lung Carcinoma 4 Sarcoma 4 Ovarian Neoplasms 4 Locally Advanced Rectal Cancer 4 Colonic Neoplasms 4 Advanced NSCLC 4 Urinary Bladder Neoplasms 3 Prostatic Neoplasms 3 Liver Neoplasms 3 Leukemia, Myeloid, Acute 3

Interventions

Etoposide 3 Carboplatin 3 Paclitaxel 2 sintilimab 1 pembrolizumab 1 olaparib 1 ceralasertib 1 atezolizumab 1 apatinib 1 anlotinib 1 Topotecan 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × SCLC × Immune Checkpoint Inhibitors × Clear all

NCT07110103 2026-02-27

JACKPOT38

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡